Results 281 to 290 of about 2,540,555 (296)

Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial

Lancet, The, 2019
Hertzel C Gerstein, Helen Colhoun, Gilles R Dagenais   +2 more
exaly  

Preventing type 2 diabetes

Nursing Standard, 2016
openaire   +2 more sources

Managing diabetes with nanomedicine: challenges and opportunities

Nature Reviews Drug Discovery, 2014
Omid Veiseh, Benjamin C Tang, Kathryn A Whitehead   +2 more
exaly  

Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes

New England Journal of Medicine, 2015
Bernard Zinman Cm, Christoph Wanner, John M Lachin   +2 more
exaly  

Primary care-led weight management for remission of type 2 diabetes (DiRECT): an open-label, cluster-randomised trial

Lancet, The, 2018
Naomi Brosnahan, George Thom, Louise Mccombie   +2 more
exaly  

Engineering immunomodulatory biomaterials for type 1 diabetes

Nature Reviews Materials, 2019
Cherie L Stabler, Ying Li, Benjamin G Keselowsky   +2 more
exaly  

Molecular and metabolic mechanisms of insulin resistance and β-cell failure in type 2 diabetes

Nature Reviews Molecular Cell Biology, 2008
Christopher B Newgard, Deborah M Muoio, Ashley Williams   +2 more
exaly  

Excess mortality and cardiovascular disease in young adults with type 1 diabetes in relation to age at onset: a nationwide, register-based cohort study

Lancet, The, 2018
Araz Rawshani, Naveed Sattar, Ann-Marie Svensson   +2 more
exaly  

A metagenome-wide association study of gut microbiota in type 2 diabetes

Nature, 2012
Shenghui Li, Jianfeng Zhu, Suisha Liang
exaly  

Diabetes, Type 2

2004
Fernando Ovalle, W. Timothy Garvey
openaire   +1 more source